Related Experiment Video
Updated: Jun 7, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Parameters for individualizing systemic therapy in non-small cell lung cancer
Shirish M Gadgeel1, Michele L Cote, Ann G Schwartz
1Department of Oncology, Wayne State University, MI 48201, USA.
Summary
Precision therapy in non-small-cell lung cancer (NSCLC) uses molecular knowledge to guide treatment selection. This approach optimizes patient outcomes by matching individuals to targeted or cytotoxic therapies, improving efficacy and quality of life.
Area of Science:
- Oncology
- Pharmacogenomics
- Translational Medicine
Background:
- Molecularly targeted drugs are transforming cancer care.
- Personalized medicine, including individualized, precision therapy, requires leveraging molecular knowledge for patient selection.
- Non-small-cell lung cancer (NSCLC) treatment selection is complex.
Purpose of the Study:
- To summarize current knowledge on selecting systemic targeted and cytotoxic therapies for NSCLC patients.
- To present a decision algorithm for optimizing patient selection for available NSCLC therapies.
- To discuss the role of predictive biomarkers and future research directions.
Main Methods:
- Review of current knowledge on patient selection for NSCLC therapies.
- Development of a potential decision algorithm for therapy selection.
- Discussion of available targeted agents (erlotinib, gefitinib, crizotinib) and cytotoxic regimens (gemcitabine/platinum, platinum/pemetrexed, taxane/non-platinum, bevacizumab combinations).
Main Results:
- Current NSCLC therapies include single-agent targeted drugs, combination chemotherapy, and bevacizumab.
- Predictive biomarker data often comes from subgroup analyses; prospective incorporation into trials is needed.
- A decision algorithm can aid in selecting appropriate therapies based on molecular profiles.
Conclusions:
- Personalized medicine in NSCLC aims to maximize therapeutic potential through molecularly guided patient selection.
- Prospective integration of biomarkers into clinical trials is crucial for refining selection parameters and understanding marker interactions.
- Future advancements will enhance clinical decision-making, leading to increased efficacy, reduced toxicity, and improved patient quality of life.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...